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ABSTRACT: Oligonucleotides are promising drug candidates due to the exceptionally high specificity they exhibit toward their
target DNA and RNA sequences. However, their poor pharmacokinetic and pharmacodynamic properties, in conjunction with
problems associated with their internalization by cells, necessitates their delivery through specialized carrier systems for efficient
therapy. Here, we investigate the effects of carrier morphology on the cellular internalization mechanisms of oligonucleotides by
using self-assembled fibrous or spherical peptide nanostructures. Size and geometry were both found to be important parameters
for the oligonucleotide internalization process; direct penetration was determined to be the major mechanism for the
internalization of nanosphere carriers, whereas nanofibers were internalized by clathrin- and dynamin-dependent endocytosis
pathways. We further showed that glucose conjugation to carrier nanosystems improved cellular internalization in cancer cells
due to the enhanced glucose metabolism associated with oncogenesis, and the internalization of the glucose-conjugated peptide/
oligonucleotide complexes was found to be dependent on glucose transporters present on the surface of the cell membrane.
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■ INTRODUCTION
Therapeutic oligonucleotides such as aptamers, CpG oligonu-
cleotides, siRNAs, and antisense oligonucleotides have received
considerable attention in the pharmaceutical industry for their
ability to selectively inhibit the activity of nucleic acid
sequences.1−3 Unlike small molecule drugs, oligonucleotides
can be designed to specifically target a broad range of
biologically relevant mechanisms, which makes them highly
attractive molecules for the treatment of conditions such as
cardiovascular diseases, metabolic diseases, cancer, and genetic
disorders.3−5 However, oligonucleotide drugs invariably suffer
from high degradation rates and short half-lives in the plasma,
and although their stability can be improved through chemical
modification, their susceptibility to nucleolytic enzymes and
rapid clearance by renal filtration and reticuloendothelial
activity are nonetheless major issues for the success of their
pharmaceutical applications. Consequently, many oligonucleo-
tide-based clinical trials have suffered due to problems
associated with low biodistribution and poor pharmacokinetic
and pharmacodynamic properties.6,7
Drug delivery systems are able to prevent the exposure of
drug molecules to biological environments, greatly increasing
their stability and improving their pharmacokinetic and
pharmacodynamic properties. As such, delivery vehicles are
an ideal means of bypassing the limitations of oligonucleotide-
based therapeutic agents. Carrier systems intended for
oligonucleotide delivery should be able to protect their cargo
from enzymatic degradation and immune system recognition
and prevent their reticuloendothelial system clearance and
rapid renal excretion. The cellular internalization of oligonu-
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cleotides has been shown to be increased when cationic lipids,8
polymers,9 and nanoparticles10−12 are used as carrier systems.
However, the size and morphology of a carrier system are also
important for determining the mechanisms of its internal-
ization; thus, a better understanding of these factors and their
impacts is vital for the development of new delivery systems.
Nevertheless, the effect of size and geometry in drug delivery
has previously been described only for a limited number of
materials and cell types, and further investigation is necessary to
improve our basic understanding of the carrier internalization
process.13,14
Glucose molecules can be utilized for targeting tumor tissue,
as cancer cells tend to overexpress glucose receptors to meet
their heightened metabolic demands.15 This tendency, which
typically accompanies a switch from oxidative phosphorylation
to glycolysis for ATP production,16 is known as the Warburg
effect17 and is considered to be one of the hallmarks of
cancer.18 Consequently, cancer cells consume more glucose
than their healthy counterparts and must overexpress certain
glucose transporters to increase their glucose uptake. The
glucose transporter GLUT1, for example, is overexpressed in
many cancer types, including breast cancer,19 renal cell
carcinomas (RCCs),20 and colorectal cancer.21 Glucose trans-
porters can also be targeted to monitor cancer activity and
progression, as the expression of GLUT1 was found to be
correlated with invasiveness of breast cancer22 and inversely
correlated with prognosis of cancer.23 Other than the GLUT
family, the expression of sodium-dependent glucose trans-
porters (SGLT1 and SGLT2) was also found to be related to
cancer survival in pancreatic adenacarcinoma24 and metastasis
of lung cancer.25 Glucose-conjugated anticancer drugs have
been shown to target tumor tissue based on increased glucose
uptake in cancer cells: glufosfamide,26 paclitaxel,27 doxorubi-
cin,28 and tamoxifen29 glycoconjugates were synthesized and
tested for cancer targeting, and glucose conjugation was found
to enhance the solubility and cellular uptake of these drugs.
Many clinical trials also utilized glycoconjugates for targeting
tumors and decreasing side effects of chemotherapeutics.30 The
Scheme 1. Schematic Representations of Peptide Amphiphiles and Their Self-Assembly into Nanospheres or Nanofibers
Figure 1. (a) Chemical structures of amphiphilic glycopeptides Lauryl-VVAGKS(β-D-Glc)-Am (Glc-K-PA) and Lauryl-P3GKS(β-D-Glc)-Am (Glc-
P-PA) and peptide amphiphiles Lauryl-VVAGK-Am (K-PA) and Lauryl-P3GK-Am (P-PA). (b) CD spectra of PA and PA/AON complexes.
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effective dose in glycoconjugates can be decreased compared to
that in nonconjugated anticancer drugs; however, a major
drawback of glycoconjugate drugs is that the drug chemical
structure changes after this conjugation and glucose needs to be
enzymatically cleaved off for pharmaceutical activity.31 Non-
covalent functionalization can eliminate this drawback, and
glucose-functionalized polymeric micelles were recently de-
scribed for this purpose.32,33
Self-assembled peptide amphiphile (PA) nanofibers have
previously been shown to be effective for antisense
oligonucleotide (AON) delivery.34 PA molecules are biocom-
patible and their degradation products are natural biomolecules
that can be metabolized in the body, which allows their use as
delivery agents with minimal side effects. Peptide-based carrier
nanostructures are also easy to produce and self-assemble
directly following the mixing of oligonucleotides with PAs. The
sequences of the peptides can also be designed to incorporate
cancer-targeting moieties for specific delivery into tumors. In
this work, we investigate the effect of morphology on the
delivery efficiency of two distinct PA-based carrier systems,
which were designed to self-assemble into nanofibers or
nanospheres by tuning the noncovalent interactions responsible
for triggering the aggregation of the PA molecules (Scheme 1).
In addition to carrier morphology, we also utilized glucose
functionalization to study the mechanisms involved in the
internalization of glucose-functionalized and nonfunctionalized
delivery vehicles.
■ RESULTS AND DISCUSSION
Peptide amphiphile molecules (K-PA and P-PA) and
amphiphilic glycopeptides (Glc-K-PA and Glc-P-PA) in Figure
1 were synthesized using solid phase peptide synthesis and
characterized by LC-MS (Figure S1). Glc-K-PA and K-PA were
designed with a Val-Val-Ala peptide sequence followed by a
hydrophilic lysine residue to allow their complexation with
oligonucleotides, and this motif was replaced with three proline
residues in Glc-P-PA and P-PA. The targeting molecule D-
glucose (β-D-Glc) was conjugated onto the peptide sequence
by using serine-linked glucose for both Glc-K-PA and Glc-P-
PA. Whereas the Val-Val-Ala sequence facilitates β-sheet
formation through hydrogen bonding among the peptide
molecules, proline residues serve as β-sheet breakers by
disrupting β-sheet secondary interactions.35,36
The self-assembly mechanisms of these systems are shown in
Scheme 1. When dissolved in an aqueous solution, PA
molecules self-assemble into nanostructures that contain
hydrophobic amino acid residues and an alkyl tail on their
interior and present their hydrophilic sections on their exterior.
Glc-K-PA and K-PA molecules, which contain β-sheet forming
regions and exhibit a positive charge at neutral pH, form
cylindrical nanostructures as a result of their complexation with
negatively charged oligonucleotides. In contrast, Glc-P-PA and
P-PA possess β-sheet breaking proline residues and form
spherical nanostructures upon the neutralization of their lysine
side chain with oppositely charged oligonucleotides. In
addition, both of the amphiphilic glycopeptides (Glc-P-PA
and Glc-K-PA) self-assembled into nanostructures that present
the glucose unit on their periphery, further enhancing cell−
material interactions.
The secondary structure (Figure 1b), morphology (Figure
2), size (Figure S2), and zeta potentials (Table S1) of the self-
assembled peptide−oligonucleotide nanostructures were stud-
ied. The secondary structures of the PAs were investigated with
circular dichroism (Figure 1b), and Glc-K-PA and K-PA were
found to form β-sheet structures in the presence of AONs at
physiological pH, as suggested by a positive peak at around 193
nm and a negative peak at around 217 nm. In the absence of
AONs, the negative peak at 217 was weakened in the K-PA
solution and disappeared entirely in the Glc-K-PA solution, and
a negative peak at 197 nm appeared for both PAs, indicating a
random coil conformation. On the other hand, the proline-rich
PAs Glc-P-PA and P-PA showed mixtures of random coil and
poly proline helix (PPII) secondary structures with a strong
negative band at 203 nm and weak positive band at 226
nm.37−39 The secondary structures of proline-rich peptides
were preserved after their complexation with AONs.
TEM images were acquired to observe the morphologies of
nanostructures in the presence of AONs (Figure 2). K-PA and
Glc-K-PA molecules formed nanofibers in the presence of
AONs with fiber diameters of approximately 10 nm. The
presence of AONs appears to allow a complete self-assembly
process with β-sheets as the predominant secondary structure,
supporting our CD results. TEM images of P-PA/AON and
Glc-P-PA/AON complexes, in contrast, suggest that the
proline-rich PAs assemble into spherical nanostructures with
diameters of 50−100 nm. The hydrodynamic sizes of P-PA/
AON and Glc-P-PA/AON nanospheres were determined to be
approximately 70 nm after DLS measurements (Figure S2).
The complexation was also confirmed with zeta potential
measurements (Table S1), as the charge of the system
decreased following the addition of the negatively charged
AONs onto the PAs.
The biocompatilibity of nanofibrous and nanospherical
systems was investigated by using the MCF-7 cell line with
24 h of culture (Figure S3). No significant decrease in cell
viability was observed at 30 μM; accordingly, PA molecules
were used at this concentration for in vitro experiments.
The cellular internalization of the PA/AON nanocomplexes
was visualized by confocal microscopy following staining nuclei
with TO-PRO-3 and actin filaments with phalloidin (red color
shows FAM-AON). The PA/AON complexes were incubated
for 4 h (Figure S4) and 24 h (Figure 3) to investigate their
Figure 2. TEM images of PA/AON complexes at a 30:1 PA/AON
molar ratio. Scale bars: 50 nm.
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cellular internalization. The nanofibers, and especially K-PA/
AON, were observed to bind better to the cell membrane,
which suggests that the internalization of AON might be slower
in nanofibers compared to nanospheres (Supporting Movies 1
and 2). During live imaging of cellular internalization,
nanospheres were observed to be internalized during the first
5 min, whereas cells only started to internalize nanofibers after
30 min of incubation. The rapid uptake of nanospheres could
be due to their direct transduction through the cell membrane.
The uptake after 24 h was also quantified with flow cytometry,
and in contrast with our short-term internalization results, the
cellular internalization of nanofibers was observed to be more
efficient compared to that of nanospheres. These results show
that, although nanofibers appear to enter the cells later than
nanospheres (after 30 min), they are able to deliver a greater
amount of AONs into cells at 24 h compared to the
nanospherical carrier system.
Because of the Warburg effect, glucose units can be used to
increase the cellular uptake of nanostructures into cancer cells.
This increase in uptake is a result of overexpressed glucose
transporters on the cell surface.15 In accordance with this
phenomenon, the cellular entry of Glc-K-PA/AON was found
to be enhanced compared to that of K-PA/AON (Figure 4);
however, no difference between the internalization of P-PA/
AON and Glc-P-PA/AON was observed. The reason behind
this lack of enhancement in nanosphere carriers may be the fact
that different internalization pathways are utilized for the entry
of nanofibers and nanospheres. Consequently, internalization
mechanisms of the PA delivery systems were assessed to
determine whether this is the case.
Supramolecular shape of the nanostructures was shown to
have a significant effect on the cellular internalization
mechanism.40 Studies conducted with peptide-based materials
revealed that cylindrical morphology results in both enhanced
delivery efficiency and an increased number of potential
binding sites compared to those of spherical counterparts due
to the multivalent presentation of bioactive epitopes along the
long-axis of the nanofiber.41−43 The possible mechanisms of
internalization are direct penetration and endocytosis (clathrin-
mediated endocytosis, caveolae-mediated endocytosis, and
micropinocytosis), and the effect of various types of
endocytosis inhibitors (amiloride, dynasore, chlorpromazine,
and nystatin) on the internalization of nanofibers and
nanospheres was determined through flow cytometry.
Amiloride inhibits micropinocytosis, dynasore inhibits dyna-
min-dependent endocytosis, chlorpromazine inhibits clathrin-
mediated endocytosis, and nystatin inhibits caveolae-mediated
endocytosis.44 Nearly no inhibition in uptake was observed for
nanospheres (P-PA/AON and Glc-P-PA/AON) in the
presence of endocytosis inhibitors, suggesting that nanosphere
internalization occurs by direct transduction through the cell
membrane (Figure 5). This result is consistent with our
observations during live confocal imaging, where spheres
entered into cells in the first 5 min of incubation. The smaller
size of nanospheres might support their rapid entry into cells.45
There is a small decrease in the uptake of nanospheres in
amiloride- and dynasore-treated cells, which suggested that
spheres could enter cells via micropinocytosis and through
dynamin-dependent pathways. This rapid and diffusion-
mediated internalization is a possible reason for the lack of
additional uptake in glucose-conjugated nanospheres.
Nanofiber internalization, on the other hand, was inhibited
by amiloride, dynasore, and chlorpromazine, suggesting that
nanofiber uptake occurs by micropinocytosis, dynamin-depend-
ent endocytosis, and clathrin-mediated endocytosis (Figure 5).
Although Glc-K-PA/AON exhibited a decrease in uptake in
response to amiloride treatment, no change was observed in K-
PA/AON, which might due to the effect of amiloride on the
inhibition of the glucose transporter mechanism.46 These
results show that the internalization of nanofibers is energy-
dependent and that they are taken up by cells mostly by
endocytosis, whereas nanospheres mostly enter cells passively.
This difference in internalization pathway might result from the
size and geometry of the self-assembled nanostructures, as
membrane wrapping times of nanoparticles were previously
shown to depend on their sizes and shapes.45 According to our
results, nanospheres (which have smaller aspect ratios) can pass
easily through the cell membrane, whereas high-aspect-ratio
nanofibers require energy-dependent pathways for internal-
ization. In addition, nanofiber internalization is slower and must
be mediated through endocytic vesicles, whereas nanospheres
are able to diffuse through the cell membrane following their
internalization. Consequently, the overall internalization of the
Figure 3. Twenty-four hours of cellular internalization of PA/AON
complexes in MCF7 cells with FAM-AON in red, actin in green, and
nuclei in blue. Scale bars: 20 μm.
Figure 4. Cellular internalization of PA/AON complexes after 24 h
quantified with flow cytometry. Error bars show SEM; two
independent experiments were repeated with n = 3 in each experiment.
Student’s t test shows statistical significance with *p < 0.05, **p <
0.01, and ***p < 0.001.
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nanofibers at 24 h was greater than that of nanospheres, as
nanofibers cannot leave the intracellular environment whereas
nanospheres can diffuse back out through the cell membrane.
Variances were also observed in the internalization
mechanisms of glucose-conjugated PAs. In particular, the
uptake of Glc-K-PA/AON was increased compared to that of
K-PA/AON (Figure 3 and Figure 4) because the glucose
moiety increases interactions between nanofibers and the cell
membrane. The glucose transporter inhibitors phloridzin
dihydrate (also known as phloridzin) and cytochalasin B were
used to further analyze the effect of glucose conjugation on the
internalization of nanofibrous AON delivery systems. The
expression of glucose transporters GLUT1, GLUT2, GLUT5,47
GLUT12,23 and SGLT148 was previously shown in MCF-7
cells. Of these, phloridzin specifically inhibits SGLT1 and
SGLT2 and minimally inhibits GLUTs,49 and cytochalasin B
inhibits glucose transport50 by inhibiting GLUT transporters
(especially GLUT1−4).51 We observed a decrease in the
internalization of Glc-K-PA/AON following phloridzin treat-
ment, suggesting that the uptake of the glycopeptide nano-
fibrous oligonucleotide delivery system is mediated by its
interactions with the sodium-dependent glucose transporter
SGLT1 (Figure 6). Strikingly, phloridzin decreased the uptake
of Glc-K-PA/AON almost to the level of K-PA/AON,
demonstrating that glucose conjugation increases cellular
internalization by promoting the binding of the nanofiber to
glucose transporters. Even in the presence of GLUT and
SGLT1 inhibitors, other glucose receptors might still be
functional and may contribute to the internalization.23,52 On
the other hand, it has been previously shown that the
internalization of glucose-conjugated nanoparticles may be
facilitated by caveolae- and clathrin-mediated endocytosis.53−55
Although the chemical and biological inhibitors of specific
cellular uptake mechanisms provide valuable tools for the study
of cellular internalization mechanisms of nanomaterials, their
interactions with the nanomaterials might change the overall
characteristics of the nanomaterials, such as surface charge,
which is an important determinant of cell uptake rate.
Figure 5. Uptake mechanism analyses of (a) P-PA/AON, (b) Glc-P-PA/AON, (c) K-PA/AON, and (d) Glc-K-PA/AON complexes. Percent uptake
in MCF-7 cells after 24 h normalized to the without inhibitor group (wo inh). Amiloride (Amil), dynasore (Dyna), chlorpromazine (Chlor), and
nystatin (Nys) were administered to cells to inhibit endocytosis pathways. Error bars show SEM; two independent experiments were repeated with n
= 3 in each experiment. One-way ANOVA analysis was performed. Statistical significance is shown with *p < 0.05, **p < 0.01, and ***p < 0.001.
Figure 6. Glucose transporter-mediated uptake mechanisms of PA/
AON complexes. Percent uptake in MCF-7 cells after 24 h normalized
to the without inhibitor group (wo inh). Phloridzin dihydrate (Phlor)
and cytochalasin B (Cyto B) were administered to cells to inhibit
glucose transporters. Error bars show SEM with n = 3. Two-way
ANOVA was performed. Statistical significance is shown with *p <
0.05, **p < 0.01, and ***p < 0.001.
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■ CONCLUSIONS
In this study, we utilized self-assembled peptide amphiphile
nanostructures with distinct geometries (nanofibers and
nanospheres) to investigate the effect of the shape of the
delivery system on the cellular internalization of oligonucleo-
tides. We observed that the size and shape of the delivery
system are important parameters for the cellular internalization
of the ODN cargo. Whereas nanospheres were found to enter
cells directly, nanofibers were internalized by dynamin- and
clathrin-mediated endocytosis. The internalization of nano-
spheres was a rapid process, whereas the uptake of nanofibers
took more time. However, fibers were found to carry more
oligonucleotides into cells under long-term observation, as
nanospheres are able to diffuse out of the cells despite their
rapid uptake. Peptide amphiphiles were also functionalized with
glucose units to produce glycopeptide delivery systems, which
enhanced AON delivery through glucose transporter-mediated
internalization in the nanofiber system (but did not yield any
enhancement in performance in the nanosphere system due to
differences in uptake mechanisms). Thus, glucose-function-
alized, self-assembling peptide amphiphiles can be useful for
clinical oligonucleotide delivery, although future carrier designs
should also consider that the effectiveness of targeting and
internalization-enhancing moieties may depend on the size and
morphology of the carrier.
■ EXPERIMENTAL SECTION
Materials. 9-Fluorenylmethoxycarbonyl (Fmoc)- and tert-butox-
ycarbonyl (Boc)-protected amino acids, except glyco amino acid, [4-
[α-(2′ ,4′-dimethoxyphenyl) Fmoc-aminomethyl]phenoxy]-
acetamidonorleucyl-MBHA resin (Rink amide MBHA resin), and 2-
(1H-benzotriazol-1-yl)-1,1,3,3 tetramethyluronium hexafluorophos-
phate (HBTU), were purchased from NovaBiochem. Fmoc-Ser[β-
Glc(OAc)4]-OH was purchased from AAPPTec. Lauric acid and N,N-
diisopropylethylamine (DIEA) were purchased from Merck. Other
chemicals were purchased from Alfa Aesar or Sigma-Aldrich and used
as provided. All water used was deionized water with a resistance of 18
MΩ cm (Millipore Milli-Q). Cell culture media, fetal bovine serum,
penicillin-streptomycin, and trypsin were purchased from Gibco, Life
Technologies. Bcl-2 antisense oligonucleotide (G-3129, Genasense)-
and fluorescein-6-amide (FAM)-labeled antisense oligonucleotide
having the same sequence were donated by Genta Inc.
Peptide Synthesis and Characterization. 9-Fluorenylmethox-
ycarbonyl (Fmoc) chemistry was used to synthesize peptide
amphiphiles and amphiphilic glycopeptides. PA molecules were
constructed on MBHA rink amide resin (loading = 0.56 mol/g) and
prepared on 0.25 mmol scale. All amino acid couplings were manually
performed with 2 equiv of Fmoc-protected amino acid, 1.95 equiv of
HBTU, and 3 equiv of N,N-diisopropylethylamine (DIEA) in DMF
for 3 h. Lauric acid was conjugated to the N-terminal of the peptide by
the addition of the same reagents used for amino acid couplings. Each
coupling reaction was monitored by ninhydrin test. Fmoc depro-
tections were performed with 20% piperidine/dimethylformamide
(DMF) solution for 20 min. Cleavage of the peptides from the resin
was carried out with a mixture of trifluoroacetic acid (TFA)/
triisoproplysilane (TIS)/water at a ratio of 95:2.5:2.5 for 2 h. Excess
TFA was removed by rotary evaporation. The remaining viscous
peptide solution was treated with ice-cold diethyl ether, and the
resulting white pellet was freeze-dried. For glycopeptides, acetyl
protecting groups on glucose were removed in solution phase with
NaOMe (1.2 equiv excess with respect to acetyl groups, 2 M) in
methanol. The reaction was carried out at room temperature for 3−4
h. For quenching the reaction, the solution was neutralized with a few
drops of acetic acid. The solution was then collected, dissolved in
water, and freeze-dried. All peptides were purified on an Agilent 1200
HPLC using an Agilent Zorbax 300SB-C8 (21.2 × 150 mm) column
with a water (0.1% TFA)/acetonitrile (0.1% TFA) gradient. The final
purified peptides were characterized by reverse-phase HPLC on an
Agilent 6530 accurate-Mass Q-TOF LC/MS equipped with an Agilent
1200 HPLC. A Phenomenex Luna 3 μ C8 100A (50 × 3.00 mm)
column and a water (0.1% formic acid)/acetonitrile (0.1% formic acid)
gradient were used as stationary phase and mobile phase, respectively.
Peptides with a purity of more than 95% were used in the experiments.
Circular Dichroism. PA samples were prepared at a final
concentration of 200 μM in water, and PA/AON combinations were
prepared at a 30:1 PA/AON molar ratio. Quartz cuvettes with 1 mm
path lengths were used for all measurements. Circular dichroism
analysis was performed with a J-815 Jasco spectrophotometer in the far
UV region. Parameters were selected as follows: integration time of 4
s, bandwidth of 1 nm, and data pitch of 0.1 nm. An average of three
readings between 190 and 260 nm were collected for each sample.
Ellipticity was converted to molar ellipticity with the unit degree cm2
dmol−1.
Transmission Electron Microscopy. TEM samples were
prepared on a 200-mesh copper grid. Dilute solutions of PA/AON
complexes at 0.05% (w/v) and 50 ng/μL of AON concentrations were
used for TEM analysis. Samples were dropped on copper grids,
incubated for 5 min, and stained with 2 wt % uranyl acetate for 3 min
following the removal of excess solution. After washing, samples were
air-dried, and images were obtained with a FEI Tecnai G2 F30 TEM at
200 keV.
Maintenance of Cells and Transfection with PA and PA/AON
Complexes. Cells were maintained in standard medium containing
Dulbecco’s modified eagle medium (DMEM) with 10% fetal bovine
serum (FBS) and 1% penicillin−streptomycin and passaged at cell
confluency between 80 and 90% using trypsin−EDTA. In transfection
experiments, PA/AON complexes were prepared in ddH2O to have a
molar ratio of 30:1 and administered in serum-free medium (1%
penicillin−streptomycin-containing DMEM).
Cellular Internalization of PA/AON Complexes. Thirteen
millimeter glass coverslips were placed in 24-well plates, and 4 ×
104 MCF7 cells per well were seeded in standard medium. After 24 h,
medium was discarded, and PA/AON complexes were administered in
serum-free medium. The AON final concentration was set to 1 μM,
and the PA concentration was adjusted accordingly. After incubation,
cells were washed with PBS three times, fixed with 4%
paraformaldehyde, and stained with phalloidin and TO-PRO-3. Cells
were visualized with a laser scanning confocal microscope (LSM 510,
Zeiss).
Mechanisms of Internalization. Small molecule chemical
inhibitors were used to inhibit specific internalization pathways for
investigating the internalization mechanism of PA/AON complexes.
Inhibitor concentrations were adjusted in a preliminary experiment,
and the maximum dose that did not induce cell death was selected for
testing. Thus, 8 × 104 MCF-7 cells/well were seeded in standard
medium in 24-well plates. After 24 h, medium was removed, and 400
μL of serum-free medium was added. Then, 50 μL inhibitor solutions
were administered to a final concentration of 100 μM amiloride, 20
μM dynasore, 0.2 μg/mL of chlorpromazine, or 10 μg/mL of nystatin.
In addition, final concentrations of 1000 μM phloridzin dihydrate and
50 μM cytochalasin B were used in glucose transporter inhibition
studies. After 1 h of incubation, PA/AON complexes were
administered to have a final concentration of 30 μM PA and 1 μM
AON. Cells were incubated for another 24 h and collected in
eppendorf tubes following trypsinization. After washing with PBS two
times and centrifugation at 1500 rpm for 5 min, cells were dissolved in
PBS. Cells were then trypsinized, kept on ice, and analyzed with a
Guava easycyte flow cytometer (Milipore). Cells were gated by side
scatter channel (SSC) and forward scatter channel (FSC) using a
nontreated control. The fluorescence intensity of FAM-AONs was
measured with the green channel.
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